Symbiotec PharmaQ1 FY27

Symbiotec Pharma Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,600.6P/E: 69.6Market Cap: ₹10.3K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2
No information is provided regarding the same in the latest conference call.

See what Symbiotec Pharma management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
No information is provided regarding the same in the latest conference call.

See what Symbiotec Pharma management said on order book — free account, 30 seconds.

Capex plans

Yes
No information is provided regarding the same in the latest conference call.

Track Symbiotec Pharma — get its next earnings analysis in your feed

How does Symbiotec Pharma rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisSymbiotec Pharma
Rev 2Mar 3

How does Symbiotec Pharma rank in Pharmaceuticals & Biotechnology?

Compare Symbiotec Pharma against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Symbiotec Pharma's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →